Resveratrol suppresses neuroinflammation to alleviate mechanical allodynia by inhibiting Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway in a rat model of spinal cord injury.
Janus kinase 2/signal transducer and activator of transcription 3
neuroinflammation
neuropathic pain
resveratrol
spinal cord injury
Journal
Frontiers in molecular neuroscience
ISSN: 1662-5099
Titre abrégé: Front Mol Neurosci
Pays: Switzerland
ID NLM: 101477914
Informations de publication
Date de publication:
2023
2023
Historique:
received:
05
12
2022
accepted:
26
01
2023
entrez:
6
3
2023
pubmed:
7
3
2023
medline:
7
3
2023
Statut:
epublish
Résumé
Neuropathic pain (NP) is one of intractable complications of spinal cord injury (SCI) and lacks effective treatment. Resveratrol (Res) has been shown to possess potent anti-inflammatory and anti-nociceptive effects. In this study, we investigated the analgesic effect of Res and its underlying mechanism in a rat model of SCI. The rat thoracic (T10) spinal cord contusion injury model was established, and mechanical thresholds were evaluated during an observation period of 21 days. Intrathecal administration with Res (300 μg/10 μl) was performed once a day for 7 days after the operation. On postoperative day 7, the expressions of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6) were determined by enzyme-linked immunosorbent assay (ELISA) and Real-time quantitative PCR (RT-qPCR), the expression of Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway was determined by western blot and RT-qPCR, and the co-labeled phospho-STAT3 (p-STAT3) with neuronal nuclear antigen (NeuN), glial fibrillary acidic protein (GFAP), and ionized calcium-binding adapter molecule 1 (Iba-1) were explored by double immunofluorescence staining in the lumbar spinal dorsal horns. The temporal changes of p-STAT3 were investigated by western blot on the 1st, 3rd, 7th, 14th, and 21st days after the operation. Intrathecal administration with Res for 7 successive days alleviated mechanical allodynia of rats during the observation period. Meanwhile, treatment with Res suppressed the production of pro-inflammatory factors TNF-α, IL-1β and IL-6, and inhibited the expressions of phospho-JAK2 and p-STAT3 in the lumbar spinal dorsal horns on postoperative day 7. Additionally, the protein expression of p-STAT3 was significantly increased on the 1st day following the operation and remained elevated during the next 21 days, immunofluorescence suggested that the up-regulated p-STAT3 was co-located with glial cells and neurons. Our current results indicated that intrathecal administration with Res effectively alleviated mechanical allodynia after SCI in rats, and its analgesic mechanism might be to suppress neuroinflammation by partly inhibiting JAK2/STAT3 signaling pathway.
Sections du résumé
Background
UNASSIGNED
Neuropathic pain (NP) is one of intractable complications of spinal cord injury (SCI) and lacks effective treatment. Resveratrol (Res) has been shown to possess potent anti-inflammatory and anti-nociceptive effects. In this study, we investigated the analgesic effect of Res and its underlying mechanism in a rat model of SCI.
Methods
UNASSIGNED
The rat thoracic (T10) spinal cord contusion injury model was established, and mechanical thresholds were evaluated during an observation period of 21 days. Intrathecal administration with Res (300 μg/10 μl) was performed once a day for 7 days after the operation. On postoperative day 7, the expressions of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6) were determined by enzyme-linked immunosorbent assay (ELISA) and Real-time quantitative PCR (RT-qPCR), the expression of Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway was determined by western blot and RT-qPCR, and the co-labeled phospho-STAT3 (p-STAT3) with neuronal nuclear antigen (NeuN), glial fibrillary acidic protein (GFAP), and ionized calcium-binding adapter molecule 1 (Iba-1) were explored by double immunofluorescence staining in the lumbar spinal dorsal horns. The temporal changes of p-STAT3 were investigated by western blot on the 1st, 3rd, 7th, 14th, and 21st days after the operation.
Results
UNASSIGNED
Intrathecal administration with Res for 7 successive days alleviated mechanical allodynia of rats during the observation period. Meanwhile, treatment with Res suppressed the production of pro-inflammatory factors TNF-α, IL-1β and IL-6, and inhibited the expressions of phospho-JAK2 and p-STAT3 in the lumbar spinal dorsal horns on postoperative day 7. Additionally, the protein expression of p-STAT3 was significantly increased on the 1st day following the operation and remained elevated during the next 21 days, immunofluorescence suggested that the up-regulated p-STAT3 was co-located with glial cells and neurons.
Conclusion
UNASSIGNED
Our current results indicated that intrathecal administration with Res effectively alleviated mechanical allodynia after SCI in rats, and its analgesic mechanism might be to suppress neuroinflammation by partly inhibiting JAK2/STAT3 signaling pathway.
Identifiants
pubmed: 36873101
doi: 10.3389/fnmol.2023.1116679
pmc: PMC9977815
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1116679Informations de copyright
Copyright © 2023 Han, Hua, Yang, Wang, Yan, Wang and Sun.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Lett. 2021 Sep 1;515:63-72
pubmed: 34052324
Reg Anesth Pain Med. 2021 Apr;46(4):328-336
pubmed: 33408161
J Pain. 2020 Mar - Apr;21(3-4):455-466
pubmed: 31520733
Brain Res. 2011 Feb 16;1374:100-9
pubmed: 21111721
J Neurosci Methods. 1994 Jul;53(1):55-63
pubmed: 7990513
Brain. 2014 Aug;137(Pt 8):2193-209
pubmed: 24919967
J Neurochem. 2008 Oct;107(1):50-60
pubmed: 18636982
Int Immunopharmacol. 2016 May;34:165-172
pubmed: 26953646
J Neuroinflammation. 2020 Nov 27;17(1):361
pubmed: 33246465
Biomed Pharmacother. 2021 Jul;139:111563
pubmed: 33873146
Front Immunol. 2021 Jul 22;12:714943
pubmed: 34367186
Exp Neurol. 2008 Aug;212(2):337-47
pubmed: 18511041
Exp Neurol. 2018 Feb;300:212-221
pubmed: 29183675
Neurosci Lett. 2021 Sep 25;762:136151
pubmed: 34352338
J Nutr. 2002 Feb;132(2):257-60
pubmed: 11823587
Neurochem Int. 2021 Nov;150:105188
pubmed: 34536545
Biol Trace Elem Res. 2022 Dec;200(12):5104-5114
pubmed: 35059981
Int J Biol Sci. 2021 Jul 5;17(11):2795-2810
pubmed: 34345208
Spinal Cord. 2012 Jun;50(6):413-7
pubmed: 22182852
Leukemia. 2020 Jul;34(7):1805-1815
pubmed: 32518419
Cell Biochem Funct. 2021 Jun;39(4):555-561
pubmed: 33724512
J Neuroinflammation. 2016 Jun 17;13(1):152
pubmed: 27316678
Brain Res Rev. 2009 Apr;60(1):202-13
pubmed: 19154757
Arch Phys Med Rehabil. 2007 Nov;88(11):1384-93
pubmed: 17964877
Reg Anesth Pain Med. 2013 Mar-Apr;38(2):93-9
pubmed: 23337935
Curr Pain Headache Rep. 2012 Jun;16(3):207-16
pubmed: 22392531
J Neurol Sci. 2018 Jan 15;384:75-83
pubmed: 29249383
Molecules. 2021 Jan 05;26(1):
pubmed: 33466247
Cell Rep. 2020 May 19;31(7):107657
pubmed: 32433966
J Neurochem. 2006 Feb;96(4):1060-70
pubmed: 16417589
J Neurochem. 2006 Sep;98(5):1353-68
pubmed: 16923154
Anesthesiology. 2016 Apr;124(4):934-44
pubmed: 26808633
Mol Cell Biol. 1997 May;17(5):2497-501
pubmed: 9111318
Front Pain Res (Lausanne). 2022 Jul 28;3:933422
pubmed: 35965596
J Food Biochem. 2022 Aug;46(8):e14182
pubmed: 35415913
Front Oncol. 2018 Jul 31;8:287
pubmed: 30109213
Exp Ther Med. 2021 Jul;22(1):711
pubmed: 34007320
Curr Cancer Drug Targets. 2007 Feb;7(1):91-107
pubmed: 17305481
Pain. 2019 Dec;160(12):2724-2742
pubmed: 31365471
Front Mol Neurosci. 2022 Apr 19;15:861312
pubmed: 35514432
Protein Sci. 2018 Dec;27(12):1984-2009
pubmed: 30267440
Drug Metab Dispos. 2004 Dec;32(12):1377-82
pubmed: 15333514
Int J Mol Sci. 2019 Mar 27;20(7):
pubmed: 30934670
Anesth Analg. 2005 Nov;101(5):1422-1426
pubmed: 16244005
Mol Neurobiol. 2021 Nov;58(11):5799-5813
pubmed: 34410605
Colloids Surf B Biointerfaces. 2021 Mar;199:111532
pubmed: 33385822
Exp Ther Med. 2022 Jul 21;24(3):586
pubmed: 35949346
J Neuroinflammation. 2021 Nov 5;18(1):256
pubmed: 34740378
Neurotherapeutics. 2015 Apr;12(2):491-501
pubmed: 25588581
Lab Anim Sci. 1999 Apr;49(2):161-72
pubmed: 10331546
Eur Rev Med Pharmacol Sci. 2019 Nov;23(21):9189-9198
pubmed: 31773669
Exp Ther Med. 2013 Nov;6(5):1194-1198
pubmed: 24223643
Mater Today Bio. 2021 Dec 04;13:100177
pubmed: 34938991
Pharmacol Res. 2022 Sep;183:106377
pubmed: 35926806
J Sci Food Agric. 2020 Mar 15;100(4):1392-1404
pubmed: 31756276
J Neuroinflammation. 2022 Jun 11;19(1):144
pubmed: 35690777
Fundam Clin Pharmacol. 2007 Feb;21(1):89-94
pubmed: 17227449
Pharmacol Biochem Behav. 2006 Jul;84(3):535-42
pubmed: 16899286
Pain. 2013 Jul;154(7):1115-28
pubmed: 23639820
J Neuroinflammation. 2020 Oct 21;17(1):311
pubmed: 33081801
Neural Regen Res. 2019 Oct;14(10):1734-1742
pubmed: 31169191